Neumora Therapeutics Receives Nasdaq Bid Price Deficiency Notice

Neumora Therapeutics, Inc. (Nasdaq: NMRA) received written notice from Nasdaq that it is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market, the company said in an 8-K filed Friday, Oct. 30, 2026.

The notice was dated Oct. 26, 2026, and falls under Nasdaq Listing Rule 5450(a)(1). Under Listing Rule 5810(c)(3)(A), the company has 180 calendar days, or until April 26, 2027, to regain compliance.

What regaining compliance requires

To regain compliance, the closing bid price of the company's common stock must meet or exceed $1.00 per share for at least ten consecutive business days during the 180-day period.

What happens if the deadline passes

If the company is not in compliance by April 26, 2027, it may be eligible for additional time. To qualify, it would have to apply to transfer its listing to The Nasdaq Capital Market, meet that market's continued listing requirement for market value of publicly held shares and other initial listing standards other than the bid price test, pay an application fee, and notify Nasdaq of its intent to cure the deficiency.

If the company does not regain compliance within the allotted periods, including any extensions, Nasdaq will provide notice that the stock will be subject to delisting. The company would be entitled to appeal that determination, but the filing says there is no assurance Nasdaq would grant continued listing.

The company said it will monitor its closing bid price and consider options, including a reverse stock split of its common stock. It also said there can be no assurance it will regain compliance. The filing does not say whether trading is affected while the compliance period runs.